Patents by Inventor Eric P. Gillis

Eric P. Gillis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9732119
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: August 15, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • Patent number: 9732102
    Abstract: A protected organoboronic acid includes a boron having an sp3 hybridization, a conformationally rigid protecting group bonded to the boron, and an organic group bonded to the boron through a boron-carbon bond. A method of performing a chemical reaction includes contacting a protected organoboronic acid with a reagent, the protected organoboronic acid including a boron having an sp3 hybridization, a conformationally rigid protecting group bonded to the boron, and an organic group bonded to the boron through a boron-carbon bond. The organic group is chemically transformed, and the boron is not chemically transformed.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: August 15, 2017
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Martin D. Burke, Eric P. Gillis
  • Publication number: 20170158614
    Abstract: Provided are methods for making and using chiral, non-racemic protected organoboronic acids, including pinene-derived iminodiacetic acid (PIDA) boronates, to direct and enable stereoselective synthesis of organic molecules. Also provided are methods for purifying PIDA boronates from solution. Also provided are methods for deprotection of boronic acids from their PIDA ligands. The purification and deprotection methods may be used in conjunction with methods for coupling or otherwise reacting boronic acids. Iterative cycles of deprotection, coupling, and purification can be performed to synthesize chiral, non-racemic compounds. The methods are suitable for use in an automated chemical synthesis process. Also provided is an automated small molecule synthesizer apparatus for performing automated stereoselective synthesis of chiral, non-racemic small molecules using iterative cycles of deprotection, coupling, and purification.
    Type: Application
    Filed: July 11, 2016
    Publication date: June 8, 2017
    Inventors: Martin D. Burke, Junqi Li, Eric P. Gillis
  • Patent number: 9643999
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: May 9, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Li-Qiang Sun, Qian Zhao, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, Eric P. Gillis, Paul Michael Scola
  • Patent number: 9598433
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: March 21, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Li-Qiang Sun, Eric P. Gillis, Eric Mull, Michael S. Bowsher, Qian Zhao, Paul Michael Scola
  • Publication number: 20170002026
    Abstract: A protected organoboronic acid includes a boron having an sp3 hybridization, a conformationally rigid protecting group bonded to the boron, and an organic group bonded to the boron through a boron-carbon bond. A method of performing a chemical reaction includes contacting a protected organoboronic acid with a reagent, the protected organoboronic acid including a boron having an sp3 hybridization, a conformationally rigid protecting group bonded to the boron, and an organic group bonded to the boron through a boron-carbon bond. The organic group is chemically transformed, and the boron is not chemically transformed.
    Type: Application
    Filed: May 2, 2016
    Publication date: January 5, 2017
    Inventors: Martin D. Burke, Eric P. Gillis, Suk Joong Lee, David M. Knapp, Kaitlyn C. Gray
  • Publication number: 20160376292
    Abstract: Described are methods of forming protected boronic acids that provide in a manner that is straightforward, scalable, and cost-effective a wide variety of building blocks, such as building blocks containing complex and/or pharmaceutically important structures, and/or provide simple or complex protected organoboronic acid building blocks. A first method includes reacting an imino-di-carboxylic acid and an organoboronate salt. A second method includes reacting a N-substituted morpholine dione and an organoboronic acid.
    Type: Application
    Filed: May 31, 2016
    Publication date: December 29, 2016
    Inventors: Martin D. Burke, Graham R. Dick, David M. Knapp, Eric P. Gillis, Jenna A. Klubnick
  • Publication number: 20160376260
    Abstract: A method of performing a chemical reaction includes reacting a compound selected from the group consisting of an organohalide and an organo-pseudohalide, and a protected organoboronic acid represented by formula (I) in a reaction mixture: R1—B-T ??(I); where R1 represents an organic group, T represents a conformationally rigid protecting group, and B represents boron having sp3 hybridization. When unprotected, the corresponding organoboronic acid is unstable by the boronic acid neat stability test. The reaction mixture further includes a base having a pKB of at least 1 and a palladium catalyst. The method further includes forming a cross-coupled product in the reaction mixture.
    Type: Application
    Filed: April 29, 2016
    Publication date: December 29, 2016
    Inventors: Martin D. Burke, David M. Knapp, Eric P. Gillis
  • Patent number: 9527885
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: December 27, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sheldon Hiebert, Ramkumar Rajamani, Li-Qiang Sun, Eric Mull, Eric P. Gillis, Michael S. Bowsher, Qian Zhao, Nicholas A. Meanwell, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P.V.K. Suresh Babu, Paul Michael Scola
  • Publication number: 20160340391
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: July 7, 2016
    Publication date: November 24, 2016
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Li-Qiang Sun, Kap-Sun Yeung, Patrick C. Reid, Paul Michael Scola
  • Patent number: 9499550
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: November 22, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Li-Qiang Sun, Eric Mull, Eric P. Gillis, Michael S. Bowsher, Qian Zhao, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P.V.K. Suresh Babu, Paul Michael Scola
  • Publication number: 20160272680
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: March 14, 2016
    Publication date: September 22, 2016
    Inventors: Kenneth M. Boy, Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • Patent number: 9422311
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: August 23, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, Eric P. Gillis, Paul Michael Scola
  • Publication number: 20160222060
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: February 1, 2016
    Publication date: August 4, 2016
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Ling Li, Claudio Mapelli, Maude A. Poirier, Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • Publication number: 20160207943
    Abstract: Provided are methods for purifying N-methyliminodiacetic acid (MIDA) boronates from solution. Also provided are methods for deprotection of boronic acids from their MIDA ligands. The purification and deprotection methods can be used in conjunction with methods for coupling or otherwise reacting boronic acids. Iterative cycles of deprotection, coupling, and purification can be performed to synthesize chemical compounds of interest. The methods are suitable for use in an automated chemical synthesis process. Also provided is an automated small molecule synthesizer apparatus for performing automated synthesis of small molecules using iterative cycles of deprotection, coupling, and purification in accordance with methods of the invention.
    Type: Application
    Filed: January 15, 2016
    Publication date: July 21, 2016
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Martin D. Burke, Eric P. Gillis, Steven G. Ballmer
  • Patent number: 9388131
    Abstract: Provided are methods for making and using chiral, non-racemic protected organoboronic acids, including pinene-derived iminodiacetic acid (PIDA) boronates, to direct and enable stereoselective synthesis of organic molecules. Also provided are methods for purifying PIDA boronates from solution. Also provided are methods for deprotection of boronic acids from their PIDA ligands. The purification and deprotection methods may be used in conjunction with methods for coupling or otherwise reacting boronic acids. Iterative cycles of deprotection, coupling, and purification can be performed to synthesize chiral, non-racemic compounds. The methods are suitable for use in an automated chemical synthesis process. Also provided is an automated small molecule synthesizer apparatus for performing automated stereoselective synthesis of chiral, non-racemic small molecules using iterative cycles of deprotection, coupling, and purification.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: July 12, 2016
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Martin D. Burke, Junqi Li, Eric P. Gillis
  • Publication number: 20160176928
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 23, 2016
    Inventors: Li-Qiang Sun, Qian Zhao, Eric P. Gillis, Michael Matthew Miller, Martin Patrick Allen, Eric Mull, Paul Michael Scola
  • Publication number: 20160175386
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: December 14, 2015
    Publication date: June 23, 2016
    Inventors: Claudio Mapelli, Eric P. Gillis, Li-Qiang Sun, Qian Zhao, Martin Patrick Allen, Eric Mull, Paul Michael Scola
  • Publication number: 20160158349
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: January 28, 2016
    Publication date: June 9, 2016
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola
  • Patent number: 9353131
    Abstract: Described are methods of forming protected boronic acids that provide in a manner that is straightforward, scalable, and cost-effective a wide variety of building blocks, such as building blocks containing complex and/or pharmaceutically important structures, and/or provide simple or complex protected organoboronic acid building blocks. A first method includes reacting an imino-di-carboxylic acid and an organoboronate salt. A second method includes reacting a N-substituted morpholine dione and an organoboronic acid.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: May 31, 2016
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Martin D. Burke, Graham R. Dick, David M. Knapp, Eric P. Gillis, Jenna A. Klubnick